Live Breaking News & Updates on Cholangitis

Stay informed with the latest breaking news from Cholangitis on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cholangitis and stay connected to the pulse of your community

Seladelpar Could 'Raise the Bar' in PBC Treatment

The investigational agent significantly improved liver biomarkers of disease activity and symptoms of pruritus in adults with PBC enrolled in a phase 3 trial.

Toronto , Ontario , Canada , United-states , Connecticut , New-haven , American , Gideon-hirschfield , Davidn-assis , Toronto-center , Yale-school-of-medicine , Drug-administration

Elafibranor Appears Effective, Safe for PBC

Treatment with elafibranor showed significantly greater improvements in relevant biochemical indicators of cholestasis than the placebo.

Washington , United-states , Seattle , Kris-kowdley , Liver-institute-northwest-in-seattle , Liver-institute-northwest , New-england-journal , Worst-itch-numeric-rating-scale , Biliary-disease , Allbladder-disease , Cholangitis , Lipids

#VisualAbstract: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute-medicine-inc , Alkaline-phosphatase , Bilirubin , Cholangitis , Elafibranor , Ppar-agonist , Primary-biliary-cholangitis , Studygraphics ,

Novel Agent Seladelpar Improves Markers of PBC Activity

For 1 in 4 patients with primary biliary cholangitis (PBC) who received the investigational PPAR-delta agonist, alkaline phosphatase levels normalized.

Boston , Massachusetts , United-states , Odense , Syddanmark , Denmark , Canada , Toronto , Ontario , Australia , America , Aleksander-krag

Ricky Safer: Working to Streamline Primary Sclerosing Cholangitis Diagnoses

The founder of PSC Partners Seeking a Cure discusses how screening and treatment for the rare disease has evolved since her diagnosis 20 years ago.

Boston , Massachusetts , United-states , Liver-meeting , American-association , Liver-diseases , Ricky-safer , Primary-sclerosing-cholangitis , Psc , Psc-partners-working-fora-cure , Ricky-safe

Ode to One of the 'Deadliest Organs'

Respect and be wary of the killer gallbladder

Pennsylvania , United-states , Danville , Kentucky , Berlin , Germany , America , American , Carl-johann-august-langenbuch , Andy-warhol , John-murtha-jr , Theodor-billroth

Cell Stress Mechanisms in Liver Disease Identified

Cell Stress Mechanisms in Liver Disease Identified
by Colleen Fleiss on
April 1, 2021 at 7:11 AM
A new prognostic factor for primary sclerosing cholangitis (PSC) from liver biopsies has been identified by researchers. This is so-called cellular ER stress.
Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat, since its causes have not yet been adequately researched.
PSC is a rare disease with a poor prognosis and can lead to cirrhosis of the liver or bile duct cancer. It affects 0.01% of the population but, even though it is rare, PSC is responsible for more than 10% of all liver transplants, making it the third most common indication on liver transplant waiting lists in Europe.

United-states , American , Diseaseliver-biopsyhepatitis-aparkinsons , Insulin-delivery , Alcoholic-liver , Gender-divideandropause , Male-menopauseliverheart , Cholangitis , Liver-disease , Cell-stress , ஒன்றுபட்டது-மாநிலங்களில்

DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

DGAP-News: Immun ...
DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
vom 18.02.2021, 12:30 Uhr
Bild: pixabay.com
DGAP-News: Immunic, Inc.
/ Key word(s): Study results
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
18.02.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
- Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline -

Minnesota , United-states , Phoenix , Arizona , American , Paula-schwartz , Edna-kaplan , Keith-lindor , Johne-eaton , Daniel-vitt , Elizabeth-carey , Jessica-breu